Domperidone is Commonly Prescribed with QT-Interacting Drugs

Journal of Clinical Gastroenterology

Volumn 51, Issue 1, 2017, Pages 56-62

  Ehrenpreis, Eli D ^a   Roginsky, Grigory ^a   Alexoff, Aimee ^a   Smith, Dylan G ^a  

^a NORTHSHORE UNIVERSITY HEALTHSYSTEM   (United States)

Author keywords

arrhythmia; cytochrome P450 3A4; domperidone; drug interactions; EKG; gastroparesis prokinetic; pharmacovigilance; prescription practice; QT interval; Torsades de Pointes

Indexed keywords

AMIODARONE; AMITRIPTYLINE; AMOXAPINE; APOMORPHINE; ARSENIC TRIOXIDE; ARTEMETHER; ASENAPINE; ASTEMIZOLE; AZITHROMYCIN; CHLORPROMAZINE; CIPROFLOXACIN; CISAPRIDE; CITALOPRAM; CLARITHROMYCIN; CLOMIPRAMINE; DASATINIB; DEGARELIX; DESIPRAMINE; DISOPYRAMIDE; DOFETILIDE; DOLASETRON MESILATE; DOMPERIDONE; DOXEPIN; DRONEDARONE; DROPERIDOL; ERYTHROMYCIN; ESCITALOPRAM; FLECAINIDE; FLUCONAZOLE; UNINDEXED DRUG; ANTIEMETIC AGENT;

ADULT; ADVERSE DRUG REACTION; ARTICLE; CONTROLLED STUDY; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; ELECTROCARDIOGRAM; ELECTRONIC MEDICAL RECORD; FEMALE; FOLLOW UP; GASTROESOPHAGEAL REFLUX; HEART ARREST; HEART ARRHYTHMIA; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE FLUTTER; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRESCRIPTION; PRIORITY JOURNAL; QT INTERVAL; QT PROLONGATION; STOMACH PARESIS; TORSADE DES POINTES; AGED; CHEMICALLY INDUCED; DRUG INTERACTION; DYSPEPSIA; EVALUATION STUDY; GASTROINTESTINAL DISEASE; LONG QT SYNDROME; NAUSEA; POSTMARKETING SURVEILLANCE; RETROSPECTIVE STUDY; VERY ELDERLY; YOUNG ADULT;

ADULT; ADVERSE DRUG REACTION REPORTING SYSTEMS; AGED; AGED, 80 AND OVER; ANTIEMETICS; DOMPERIDONE; DRUG INTERACTIONS; DYSPEPSIA; FEMALE; GASTROINTESTINAL DISEASES; GASTROPARESIS; HUMANS; LONG QT SYNDROME; MALE; MIDDLE AGED; NAUSEA; PRODUCT SURVEILLANCE, POSTMARKETING; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84967329207     PISSN: 01920790     EISSN: 15392031     Source Type: Journal    
DOI: 10.1097/MCG.0000000000000543     Document Type: Article

References (16)

1. Reddymasu SC, Soykan I, McCallum RW. Domperidone: review of pharmacology and clinical applications in gastroenterology. Am J Gastroenterol. 2007;102:2036-2045.
2. Ahmad N, Keith-Ferris J, Gooden E, et al. Making a case for domperidone in the treatment of gastrointestinal motility disorders. Curr Opin Pharmacol. 2006;6:571-576.
3. Drolet B, Rousseau G, Daleau P, et al. Domperidone should not be considered a no-risk alternative to cisapride in the treatment of gastrointestinal motility disorders. Circulation. 2000;102:1883-1885.
4. Djeddi D, Kongolo G, Lefaix C, et al. Effect of domperidone on QT interval in neonates. J Pediatr. 2008;153:663-666.
5. FDA Talk Paper: FDA warns against women using unapproved drug, domperidone, to increase milk production. 2004. Available at: http://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ ucm173886.htm. Accessed May 1, 2015.
6. Ortiz A, Cooper CJ, Alvarez A, et al. Cardiovascular safety profile and clinical experience with high-dose domperidone therapy for nausea and vomiting. Am J Med Sci. 2015;349: 421-424.
7. Bjornsson TD, Callaghan JT, Einolf HJ, et al. The conduct of in vitro and in vivo drug-drug interaction studies: A PhRMA perspective. J Clin Pharmacol. 2003;43:443-469.
8. Priori SG. Exploring the hidden danger of noncardiac drugs. J Cardiovasc Electrophysiol. 1998;9:1114-1116.
9. Food and Drug Administration Adverse Event Reporting System (AERS) data files. 2013. Available at: http:// www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/ Surveillance. Accessed May 1, 2015.
10. Ehrenpreis ED, Ciociola AA, Kulkarni PM. FDA-Related Matters Committee of the American College of Gastroenterology. How the FDA manages drug safety with black box warnings, use restrictions, and drug removal, with attention to gastrointestinal medications. Am J Gastroenterol. 2012;107:501-504.
11. Ehrenpreis ED, Deepak P, Sifuentes H, et al. The metoclopramide black box warning for tardive dyskinesia: effect on clinical practice, adverse event reporting, and prescription drug lawsuits. Am J Gastroenterol. 2013;108:866-872.
12. Ohtani H, Taninaka C, Hanada E, et al. Comparative pharmacodynamic analysis of Q-T interval prolongation induced by the macrolides clarithromycin, roxithromycin, and azithromycin in rats. Antimicrob Agents Chemother. 2000;44:2630-2637.
13. Moore TJ, Cohen MR, Furberg CD. Serious adverse drug events reported to the FDA, 1998-2005. Arch Intern Med. 2007;167:1752-1759.
14. Department of Health and Human Service. Office of the Inspector General, review of the Food and Drug Administration's handling of adverse drug reaction reports. 1999. Available at: https://oig.hhs.gov/oas/reports/phs/c9850001.pdf. Accessed May 1, 2015.
15. Straus SM, Sturkenboom MC, Bleumink GS, et al. Noncardiac QTc-prolonging drugs and the risk of sudden cardiac death. Eur Heart J. 2005;26:2007.
16. Hasler WL, Parkman HO, Wilson LA, et al. Psychological dysfunction is associated with symptom severity but not disease etiology or degree of gastric retention in patients with gastroparesis. Am J Gastroenterol. 2010;105:2357-2367.